SPI Pharma, Colorcon Formed Global Drug Delivery Alliance
The partnership combines supply networks for oral solid dose manufacturers to streamline product procurement and development.
Updated on Oct. 6, 2026 in Healthcare
Live Poll
Do you believe large-scale corporate partnerships generally lead to better product innovation for consumers?
SPI Pharma and Colorcon entered a strategic global partnership to distribute SPI Pharma's Drug Delivery Systems portfolio. This collaboration integrates technical support and joint business development for manufacturers of oral solid dose solutions.
Why it matters
The move aims to accelerate the growth of oral solid dose product solutions by combining SPI Pharma's specialized portfolio with Colorcon's distribution network. Operators can expect expanded access to technical training and innovation resources.
The partnership includes six distinct product lines, including Pharmaburst and Advantol 300, within the Drug Delivery Systems portfolio. The exact scale of market coverage expansion vs. the companies' previous individual reach remains unknown.
The players
SPI Pharma
A developer and manufacturer of specialized drug delivery systems and ingredients for the pharmaceutical industry.
Colorcon
A global leader in the development and supply of film coating systems and excipients for the pharmaceutical and nutritional industries.
The details
Colorcon will now manage the global distribution of the portfolio, which includes products like UltraBurst, Compressol SM, Pharmasperse 416, and S-Tab. Both organizations plan to integrate their service models by providing collaborative technical support and customer training. This operational shift centralizes procurement for clients while enabling deeper joint business development for future innovations.
Timeline
October 6, 2026: The strategic partnership was officially announced.
2026: The partnership will be highlighted throughout CPhI 2026.
Market Landscape
Consolidation of distribution and innovation services is a documented trend among pharmaceutical ingredient suppliers seeking to shorten development cycles. The partnership integration follows the industry-wide trend of highlighting new supplier service models at the CPhI international pharmaceutical events series.
Manufacturers currently using these product lines should prepare for shifts in procurement contact points as Colorcon assumes global distribution duties. Monitor communication from your existing sales representative to determine if your service agreements require updates in the coming quarter.
The takeaway
This partnership signals a shift toward integrated supplier support for oral solid dose development. Operators should track the availability of joint technical training sessions through Colorcon in the coming year to leverage these new collaborative service resources.
Further reading
For more on industry supply chain trends, visit our Healthcare section.
Live Poll
Do you believe large-scale corporate partnerships generally lead to better product innovation for consumers?
